Calix accelerates SmartBiz deployments, enabling support for more types of small businesses like medical clinics and dental practices with existing firewalls, while pre-provisioning and expanding ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

As of 3:54:19 PM EDT. Market Open. SAN JOSE, Calif., March 19, 2025--Calix, Inc. (NYSE: CALX) announced that Beacon Broadband, a subsidiary of Coos-Curry Electric Cooperative, has launched a six ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Revenue: US$831.5m (down 20% from FY 2023). Net loss: US$29.7m (down by 201% from US$29.3m profit in FY 2023). US$0.45 loss per share (down from US$0.44 profit in FY 2023). Revenue was in line ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities ...

Merck opened a 225,000-square-foot facility dedicated solely to expanding vaccine manufacturing. The Rahway-based research-intensive biopharmaceutical announced the launch of the $1 billion ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of doravirine/islatravir met its primary efficacy endpoint. The first trial enrolled patients ...

Merck opened a $1 billion, 225,000-square-foot vaccine manufacturing facility in Durham, North Carolina, as part of its U.S. expansion. The company has invested over $12 billion in U.S. capital ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...